Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Uro-Oncology
Related content
Uro-Oncology
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis
Eur Urol.
Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G, Howard H, Kapoor J, Lawrentschuk N, Siva S, Azad A, Tran B, Bolton D, Murphy DG
doi: 10.1016/j.eururo.2019.09.004.
COMMENTED
Uro-Oncology
New Anti-Androgen Compounds Compared to Docetaxel in Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Urol.
Marchioni M, Di Nicola M, Primiceri G, Novara G, Castellan P, Paul A, Veccia A, Autorino R, Cindolo L, Schips L
doi: 10.1097/JU.0000000000000636.
Uro-Oncology
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
Eur Urol.
Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, van Andel G, Clarke NW, Hulshof MC, James ND, Parker CC, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Verhagen PC, Tierney JF, STOPCAP M1 Radiotherapy Collaborators
doi: 10.1016/j.eururo.2019.02.003.
Uro-Oncology
Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities
Prostate.
Dee EC, Nezolosky MD, Chipidza FE, Arega MA, Butler SS, Sha ST, Mahal BA, Nguyen PL, Yang DD, Muralidhar V
doi: 10.1002/pros.24041.
Uro-Oncology
Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist
Prostate Cancer Prostatic Dis.
Margel D, Ber Y, Peer A, Shavit-Grievink L, Pinthus JH, Witberg G, Baniel J, Kedar D, Rosenbaum E
doi: 10.1038/s41391-020-0264-9.
COMMENTED
Uro-Oncology
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.012.
Uro-Oncology
Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer
Prostate Cancer Prostatic Dis.
Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY
doi: 10.1038/pcan.2016.58.
Uro-Oncology
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer
Nat Rev Urol
Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L, Milonas D, Van Poppel H, Berghen C, Everaerts W, Claessens F, Joniau S
doi: 10.1038/s41585-021-00514-9
Further Publications Urology
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations
Prostate
Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH
doi: 10.1002/pros.24236